Introduction
Cancer gene therapies with non-replicating viral vectors have met with limited clinical success and have several constraints. They are generally one dimensional, dependent on a single therapeutic gene to be effective against a highly complex tumor target. Moreover, the vector must infect the majority of the tumor cells to be successful. Multi-modal cancer therapies are needed that depend upon tumor cells for sustained and predictable transgene expression.
Coupling the lytic properties of the replication-selective virus (eg ONYX-015) 1, 2 with the therapeutic benefit of virally delivered transgenes to create an Armed Therapeutic Viruses platform 3 that offers an opportunity to attack the complexity of the human cancers at multiple levels. Previously, others have shown that transgenes can be delivered from the replication-competent oncolytic human adenovirus (Ad) using exogenous transcription control elements. 4, 5 Adding exogenous transcriptional control elements, however, limits the transgene packaging capacity of the viral genome. 6 Using endogenous viral expression signals (promoter, polyadenylation, splicing) could circumvent this problem and allow for the predictable expression of foreign genes over the course of the viral infection if the genes were substituted for endogenous Ad genes.
The Ad5 early region 3 transcription unit (E3) is an ideal site for developing the transgene delivery capacity of the virus since the E3 region is non-essential for viral replication in vitro. [7] [8] [9] Previous investigators interested in developing the vaccine potential of Ad took advantage of convenient restriction enzyme sites and the non-essential nature of the E3 region to insert selected vaccine candidate genes. While these genes were efficiently expressed and immune responses to the target genes were noted, these insertions disrupted nearly all the E3 region gene coding sequences to express a single transgene (reviewed in Refs 10 and 11). The E3 region, however, is a multigene transcription unit (Figure 1a ), expressing at least seven different E3 proteins through alternative promoter, splicing and polyadenylation signal usage (reviewed in Ref. 12 ). The transcriptional complexity results in E3 proteins being expressed at varying times and levels over the course of the viral infection. If individual E3 genes could be substituted for by therapeutic transgenes, the system would offer the flexibility to express multiple transgenes to varying and predictable levels over the course of the viral infection. Since E3 proteins regulate the immune response to the virally infected cell (reviewed in Ref. 13 ), deleting or retaining these genes also creates an opportunity to direct the immune response to synergize with the therapeutic transgene(s), the viral lysis of the tumor cells, or both. This paper along with the accompanying articles 14, 15 describes the development of such a system from the replicating Ad, where endogenous E3 region gene expression control signals (promoter, splicing, polyadenylation signals) are used to express the therapeutic transgene from a substituted E3 gene or region.
To begin to explore the E3 region gene delivery potential, restriction endonuclease sites were engineered into the viral sequences surrounding the E3 6.7 K and gp19 K genes (Figure 1b ). These two genes were taken out together because they are adjacent to one another in the viral genome, are encoded by the same E3 mRNA, and have overlapping open reading frames. 16 By deleting both genes, the capacity of the viral genome to package a foreign gene is extended. The E3 6.7 K protein functions in concert with the RID complex to reduce TRAIL receptor-1 and -2 cell surface expression, 17 the gp19 K protein is known to bind MHC class I molecules in the endoplasmic reticulum (ER), inhibiting their transport to the infected cell surface (reviewed in Ref. 13) . In this fashion, the virus is thought to evade detection and eradication by Ad-specific cytotoxic T lymphocytes (CTL). CTL evasion by tumor cells is also well documented and can take many forms; altered MHC class I expression, decrease and/or heterogeneity of tumor antigen, loss of adhesion or accessory molecules, immune nonresponsiveness (eg tolerance, anergy, immune ignorance, clonal deletion), the secretion or expression of immunosuppressive proteins (eg TGF␤, FasL), or changes in T cell signal transduction molecules (reviewed in . Thus, the function of the gp19 K protein is redundant in the tumor cell. Its loss, however, should ensure that normal cells infected with the virus are 'visible' to host CTLs and efficiently eradicated. Consequently, eliminating the gp19 K protein could create viruses confined by the immune system to selectively productively infect only the human tumor cells.
To examine and optimize the foreign gene delivery properties of the 6.7 K/gp19 K region in the replicating Ad, a series of genes (cytosine deaminase [CD] , tumor necrosis factor (TNF␣), p16 and H-RasS17N) were inserted into the viral genome using various combinations of endogenous and newly created restriction enzyme sites. Using the wild-type Ad5, we show that transgene expression can occur efficiently from the virus, mimicking the endogenous gene. We also demonstrate that the endogenous gene expression machinery of the virus can generate transgene expression levels superior to that achieved from a replication-defective virus using the HCMV enhancer-promoter and that this is dependent upon viral replication. Lastly, we found that the insertion site choice had effects on the transgene expression level, expression of surrounding E3 genes, and on the viral infection.
Results
Creation of a shuttle vector for expression of transgenes from the E3 6.7 K/gp19 K region The Ad5 E3 transcription unit is highly complex ( Figure  1a) , with expression of the individual E3 genes differing in levels and timing due to alternative splicing, promoter usage and multiple polyadenylation sites (reviewed in Ref. 12) . At least two identifiable gene regulatory signals surround the E3 6.7 K/gp19 K region: a non-translated exon, referred to as the y-leader (bases 28 299 to 28 490), and sequences 3Ј to the gp19 K gene that affect E3 region alternative splicing (reviewed in Ref. 12). Two endogenous restriction enzyme sites (SunI, MunI) and three newly engineered sites (PacI, NheI, PmeI) ( Figure 1b) were used in different combinations to determine which pair of sites would maximize transgene packaging capacity and expression without altering the expression of the remaining E3 genes. To analyze differences in expression levels and timing, the CD gene, whose product converts the pro-drug 5Ј-FC to the chemotherapeutic 5ЈFU(5), was chosen and four different viruses (ONYX-301, -302, -303, -304) were created (Figure 1b) . In this replicating Ad gene delivery system, transgene expression is predicted to mimic the Ad gene that it replaced since gene expression is being driven from endogenous promoters. While both the 6.7 K and gp19 K genes are encoded by the same mRNA, the initial timing of transgene expression would be predicted to most closely mimic that of the gp19 K gene. 16 In the wild-type Ad5 infection, synthesis of gp19 K was detected 8 h p.i. by Western blot (Figure 2a ). CD activity was detected at 8 h p.i. from all the recombinant viruses expressing CD (ONYX-301, -302, -303, -304, Figure 2b ) and the CD protein could be detected by Western blot analysis in all viruses by 8 h p.i. (data not shown). Therefore, as predicted, CD expression mirrors gp19 K expression. Interestingly, however, there were demonstrable differences in the levels of CD expressed, as measured by the conversion of substrate, . 22 This subtle difference between the serotypes may imply some unknown regulatory elements in the 3Ј region of the Ad5 gp19 K gene. In ONYX-301 and -302, the engineered PmeI site is located within the 120 bp sequence unique to Ad5; however, in ONYX-303 and -304, the endogenous MunI site used for the 3Ј transgene insertion site is located downstream of this sequence, removing all of the Ad5 unique 120 bp sequence. Consequently, the removal of the unique 120 bp in ONYX-303 and -304 and increased transgene expression from this virus may result from a selective increase in message a over message c. More importantly for this concept, this result favors a larger deletion in the region 3Ј to the 6.7 K/gp19 K and generates more genomic space for the insertion of the therapeutic transgene.
CD expression from
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Choice of transgene insertion site can alter the expression of neighboring E3 genes and virally induced CPE
The E3 region expresses multiple gene products. It is possible that the insertion of transgenes into the complex E3 transcription unit could alter the expression of surrounding E3 genes or other genes that derive exons or introns from the E3 region, such as fiber. To assess whether this occurs, an expression time-course analysis of viral proteins located downstream of the 6.7 K/gp19 K region was performed, using cell lysates of A549 cells infected with wild-type Ad5 or the two recombinant viruses that expressed the highest CD activity, ONYX-303 and -304. Expression levels of the adenovirus death protein (ADP, located directly downstream of the 6.7 K/gp19 K region) differed markedly, with ADP expression nearly non-existent from ONYX-303 while ONYX-304 maintained expression levels similar to those seen in the Ad5 infected cells (Figure 3a) . The expression of the E3 proteins RID␤ and 14.7 K (located downstream of the ADP gene) was also analyzed. For ONYX-304, the expression of both RID␤ and 14.7 K proteins appeared to be very similar to Ad5 in terms of both timing and levels of expression (Figure 3b, c) . In contrast, the ONYX-303 infection showed lower levels of RID␤ expression ( Figure  3b ) and a delay in expression of the 14.7 K protein ( Figure  3c) . A polyclonal antibody to the Ad5 virion detected little difference in the amount of fiber between Ad5, ONYX-303 and -304-infected cell extracts (Figure 3d ).
To ask more broadly whether the transgene insertions disrupted the viral life cycle of the recombinant viruses, A549 cells were infected with ONYX-303, -304 or Ad5 and photographed over the time-course of the infection to look for alterations in virally induced cytopathic effects (CPE). As seen in Figure 4 , the CPE induced by Ad5 and ONYX-304 is similar (compare panels C, D with panels G, H). However, the CPE seen with ONYX-303 indicates that insertion of CD into the E3 region can alter the virally induced CPE (Figure 4 compare Ad5 panels C, D and ONYX-303, panels E, F). The only difference between these two viruses is in their 5ЈCD insertion site ( Figure   Figure 3 
Expression of downstream viral genes in recombinant viruses ONYX-303 and ONYX-304. A549 cells were infected with Ad5, ONYX-303 or ONYX-304 at an MOI of 10 and harvested at the times indicated. Western blots were probed with antibodies to (a) ADP (b) RID␤ (c) 14.7 K and (d) fiber as described in the Materials and methods.
1b) which results in either retention (ONYX-304) or deletion (ONYX-303) of the 3Ј end of the y-leader sequence. While the y-leader sequence is non-coding, it is spliced on to the E3 adenovirus death protein (ADP) mRNA, whose product is crucial for proper lysis and release of viral progeny from the infected cell. 23, 24 Expression of ADP was attenuated in ONYX-303 ( Figure  3a) . While the y-leader is also present in 25-50% of the L5 message encoding the fiber protein 25, 26 there was no detectable loss of fiber protein expression (Figure 3d) . Therefore, the altered phenotype seen with ONYX-303 may involve ADP and additional undefined factors. In summary, while timing and levels of CD expression were similar between ONYX-303 and -304, the difference in the transgene insertion sites can result in dramatic changes in the expression of the surrounding E3 genes and in the virus's ability to induce CPE.
TNF␣ expression and processing from the E3 6.7 K/gp19 K region
Viruses manipulate the infected cell to maximize their replication efficiency. Therapeutic transgenes dependent upon normal cell pathways for processing and secretion may be compromised due to these virally induced alterations. The cytokine TNF␣ is normally processed from a 26 K cell-associated species to a soluble 17.5 K species. To test whether TNF␣ could be properly processed and expressed at times consistent with the previously described CD expressing viruses (ONYX-301, -304), TNF␣ was inserted into the NheI and MunI sites (the same sites used for CD insertion on ONYX-304, Figure  1b tein was reduced in ONYX-323-infected cells (data not shown) and additional studies are being conducted to resolve whether this is a function of the TNF gene sequences or an effect of the protein. In summary, the expression of the cytokine mTNF mirrored the timing of the gp19 K protein (Figure 2a ) and was correctly processed from its 26 K cell-associated form to the soluble 17.5 K species in this system.
Expression from the endogenous gene expression machinery of the virus is superior to HCMV enhancerpromoter driven expression and is dependent on viral DNA replication
Replication-defective viruses use promoters like the HCMV enhancer-promoter to maximize expression of the therapeutic protein. We were interested in whether the endogenous gene expression signals could generate levels of protein equal to or greater than those generated from the HCMV enhancer-promoter. To test this, A549 cells were infected at an MOI of 10 with either ONYX-323 (replication-competent) or AdmTNF␣ (replicationdefective), both of which express mTNF. One hour before the assay times designated, the medium was changed. This was done so that active TNF production, not cumulative, could be measured. Consequently, medium exposed for 1 h to the infected cell monolayers was colGene Therapy lected and assayed by ELISA for TNF␣ expression. Interestingly, levels of TNF␣ expressed from the replicating virus ONYX-323 were superior throughout the course of the infection to levels generated by the replication-incompetent virus AdmTNF (Figure 6a ). To determine whether this was due to viral DNA replication, araC, an inhibitor of viral DNA replication, was included and the experiment repeated. As seen in Figure 6b , a similar expression pattern was noted at early times p.i. (before viral DNA replication, 8 and 12 h p.i.). However, this changes dramatically at late times p.i. when DNA replication is inhibited (24, 36 and 48 h p.i.), with levels of mTNF expressed being severely attenuated from the replicating virus ONYX-323 compared with the non-replicating HCMV enhancer-promoter driven expression of Gene Therapy AdmTNF (Figure 6b ). It is interesting to note that the presence of araC actually enhances mTNF expression from the HCMV enhancer-promoter in the replicationdefective Ad infection (Figure 6b) .
Transgene choice and cell type do not alter expression from the E3 6.7 K/gp19 K region
It is possible that the predictability of the system is limited to select cells or transgenes. To try to address this, two additional recombinant viruses were created that encode genes for either the cell cycle regulator p16 (ONYX-330) or a dominant-negative form of Ras, HRasS17N (ONYX-340). These viruses were used to infect either A549 or U2OS cells and at various times p.i. the transgenes were assayed and compared for expression by Western blot analysis. In Figure 7 , both H-RasS17N and p16 were detected by 8 h p.i. in A549 cells, mirroring the expression of gp19 K in Ad5-infected cells (Figure 2a ) and similar to that observed for the CD-and TNF␣-expressing recombinant viruses (see Figure 2b , 5a). Importantly, while the expression timing of gp19 K changed in U2OS cells to 13 h p.i., the expression of H-RasS17N and p16 mirrored this shift in time to expression (Figure 7) . Although p16 expression appeared to occur slightly earlier than either H-ras or gp19 K in the U2OS cells ( Figure  7 ), this may reflect sensitivity differences between the antibodies. These data suggest that this system allows for expression of different transgenes from the E3 region and that this expression pattern is predictable based on the expression pattern of the endogenous genes that were replaced.
Discussion
We have developed a system for delivering therapeutic transgenes from a replicating adenovirus that has several unique properties. First, we utilize the endogenous gene expression machinery (promoter, polyadenylation and splicing signals) to express foreign genes. Second, we selectively substitute for endogenous adenoviral genes or regions in the multi-gene transcription unit E3. Using this strategy, we show that transgene expression mimics the endogenous substituted gene (Figures 2a, b, 5, 7 ) and in the case of ONYX-304, -301, -302, -330, -340, this occurs without altering expression of downstream genes ( Figure  3 , data not shown). The proteins expressed were properly processed (TNF, Figure 5a, b) , active (CD, Figure 2c ) and therefore should function in vivo. Unlike traditional vectors which employ exogenous promoters to express a sin- gle transgene at a constitutive level in the target cell, this system holds the potential of delivering multiple transgenes (substituting for the surrounding expressed E3 genes, Figure 3 ) and taking advantage of the complexity of the multi-gene E3 transcription unit to deliver these transgenes at varying times and levels over the course of the viral infection. The added benefit to this system is that high levels of transgene expression can be generated, superior to levels generated by the HCMV enhancer promoter (Figure 6a ). Maximum levels of gene expression are dependent upon viral DNA replication (Figure 6b ) and may be the result of increased copy number, enhanced promoter strength at late times p.i., or both. Importantly, eliminating expression cassettes is an economical use of a viral genome whose packaging capacity is limited in size to 105% of the wild-type adenoviral genome. 6 The choice of deleting both the 6.7 K and gp19 K genes (Figure 1b) was based on the fact that these genes are adjacent to one another in the viral genome, are encoded by the same E3 mRNA, and have overlapping open reading frames (reviewed in Ref. 12) . Consequently, by deleting both genes, the genomic capacity for a transgene insertion is extended.
The deletion of the gp19 K gene may serve to confine viral propagation to tumor cells. Both viruses and tumor cells have strategies to evade CTL generation, detection or clearance. In human Ad, the gp19 K protein complexes with the MHC class I molecule and inhibits its transport to the cell surface, effectively concealing the infected cell from detection and clearance by adenovirus-specific CTL (reviewed in Ref. 13) . CTL evasion by tumor cells can take many forms; altered MHC class I expression, decrease and/or heterogeneity of tumor antigen, loss of adhesion or accessory molecules, immune nonresponsiveness (eg tolerance, anergy, immune ignorance, clonal deletion), the secretion or expression of immunosuppressive proteins (eg TGF␤, FasL), or changes in T cell signal transduction molecules (reviewed in Refs 18-21). Consequently, this function of gp19 K is redundant in the tumor cell. More importantly, elimination of gp19 K should ensure that normal cells infected with oncolytic virus are 'visible' to host CTLs and are efficiently eradicated. Whether the adenoviral infection alone or in combination with a therapeutic gene alters susceptibility of the tumor to CTL-mediated clearance can only be formally tested in the clinical setting.
The ability to insert transgenes without disrupting the remaining E3 genes of this transcription unit has several important ramifications. First, the ADP gene lies directly downstream of the 6.7 K/gp19 K region and the protein is responsible for the efficient lysis and release of progeny virus from the infected cell. 23, 24 The importance of maintaining ADP expression is clearly demonstrated in vitro in a CPE assay with viruses ONYX-303 and -304 ( Figure  4) where the ability to maintain ADP expression in virus ONYX-304 (Figure 3 ) results in CPE similar to the wildtype infection and far superior to that seen with the ADPattenuated virus, ONYX-303. Whether retention of ADP in an in vivo setting is important remains to be determined. Second, retaining expression of the surrounding E3 genes is critical to developing viruses capable of delivering multiple transgenes. In theory, these retained E3 genes could be substituted for by therapeutic transgenes. In this fashion, each transgene could take advan-tage of the unique expression kinetics of the individually substituted E3 gene. In addition, the choice of deleting or retaining immunoregulatory E3 genes may allow the investigator to enhance or deter the immune response to synergize with the therapeutic transgene(s). For example, the E3B region genes inhibit both Fas and TNF␣-mediated toxicity (reviewed in Ref. 13 ). TNF␣ plays a major role in the clearance of the replication-defective adenoviral infection. 27 Retaining the ability of the virus to negate the innate immune response mediated by TNF␣ may be crucial to ensuring the survival of the infected cell for maximum viral replication, spread, and continued transgene expression in the tumor. However, given the immune privileged nature of the tumor, the function of these proteins may be redundant and deleting these genes may offer increased genome space.
Some of the viruses created for this initial study contain the therapeutic prodrug-converting enzyme, CD, which generates the toxic chemotherapeutic drug 5-FU (5-fluorouracil) from the nontoxic prodrug 5-FC (5-fluorocytosine). Local production of CD from an oncolytic virus at the site of the tumor coupled with intravenous non-toxic 5-FC would serve to concentrate the toxic product 5-FU to the site of the tumor. Importantly, this therapy does not require every cell in the tumor to be infected since 5-FU has a significant bystander effect. 28 Since CD can also be used as a 'suicide' gene to limit the infection, controlling the 5-FC dosing schedule is an important consideration in optimizing the therapeutic benefit of the CD-containing adenovirus.
The cytokine TNF␣ has many desirable properties for treating tumors. These include heightening tumor cell HLA expression, 29 enhancing tumor cell sensitivity to chemo- [30] [31] [32] and radio-therapies 33 and it can be lytic to both the tumor vasculature 34, 35 and the tumor cells themselves. 36, 37 However, systemic administration of this agent can have significant side-effects. [38] [39] [40] [41] By incorporating TNF into a replication-selective viral background, its expression should be concentrated to the tumor site where it can derive maximal benefit without the deleterious side-effects associated with systemic exposure.
The E3 transcription unit is an example of how viruses maximize their coding potential through the use of multiple promoters and alternative polyadenylation and splice signals. We tested the effects of altering some of these signals and have shown that careful consideration must be given when inserting transgenes into a replication-competent virus. The potential to deliver transgenes from a replicating virus offers the promise of a more viable method to deal with the complexity of the tumor microenvironment, using the lytic properties of both the productive viral infection and the therapeutic transgene. This system and its potential to deliver multiple transgene from a single replicating virus represents an important step in the rapidly evolving field of replicating virus-based therapies for cancer. (27 082) to NdeI (31 089) fragment from pNB was inserted into the multi-cloning site of pGEM5Zf+ (Promega) and the plasmid, pSN, was used for mutagenesis of the E3 6.7 K/gp19 K region. The restriction endonuclease sites engineered into this plasmid were PacI, NheI, PmeI and SwaI (see Figure 1b for location; SwaI at 30 830) and the primers used were as follows: PacC (5Ј GGAGGTGAGCTTAATTAACCCTTAGGG), PacNC (5Ј CCCTAAGGGTTAATTAAGCTCACCTCC), PmeC (5ЈTAGAATAGGGTTTAAACCCCCCGG) and PmeNC (5ЈCCGGGGGGTTTAAACCCTATTCTA), NheC (5ЈGGG TATTAGGCCAAAGGCGCAGCTAGCGTGGGG), and SwaC (5ЈCTCAAAGATCTTATTCCATTTAAATAATAAA). These primers were used in the Transformer SiteDirected Mutagenesis (Clontech, Palo Alto, CA, USA), QuickChange Site-Directed Mutagenesis (Stratagene, La Jolla, CA, USA) kits, and in PCR-based mutagenesis 44 as described. The final plasmid, pSN-PNPS, was used for all transgene insertions.
Materials and methods
Cells and viruses
Construction of E3 shuttle vectors encoding CD, TNF␣, H-ras.N17 and p16
The NdeI site in the CD gene (pCD2, ATCC No. 40999, Bethesda, MD, USA) was modified before insertion into the plasmid pSN-PNPS by PCR mutagenesis 44 using the primer CD-NdeC (5ЈGCTGCAAGTGCTGCACATGGG GCTGCATG) (details available upon request) and resulted in a silent mutation in the amino acid sequence. The altered CD gene was amplified by PCR using primers with engineered sites for insertion into the plasmid pSN-PNPS as indicated in Figure 1b . In all cases, the bacterial start codon of CD, GTG, was replaced by the eukaryotic start codon, ATG, in the primer design.
The p16, H-ras.S17N and murine TNF (mTNF) genes were isolated by PCR-based amplification from the plasmids pCMV-p16.wt, 45 pXCR-H-ras.S17N, 46 and the plasmid pMuTNF (ATCC No. 63139), respectively. The p16 and H-ras.S17N products were purified using Qiagen's QIAquick PCR purification kit (Qiagen, Santa Clara, CA, USA) and ligated directly into PCR-Script according to the manufacturer's recommendations (Stratagene). The H-ras.S17N, p16.wt and PCR amplified mTNF genes were subsequently isolated and ligated into pSN-PNPS, at the NheI and MunI sites to create pSN-TNFNheMun and the NheI and PmeI sites to create pSN-p16wtNhePme and pSN-H-ras.N17NhePme, respectively.
Construction of recombinant viruses ONYX-301,-302, -303, -304, -323, -330 and -340
The plasmids pSN-CDPacPme, pSN-CDNhePme, pSNCDSunMun, pSN-CDNheMun and pSN-mTNF NheMun were used to create the recombinant Ad viruses ONYX-301, -302, -303, -304 and -323, respectively, using the EcoRI cut and ligation method with Ad5 TP-DNA as described 47 with the following modification. The ligation mixture was introduced into A549 cells using Lipofectamine (Life Technologies, Rockville, MD, USA) as described by the manufacturer, using 13 l of Lipofectamine per transfection. Following overnight incubation, a 7 ml overlay of DME/2% FBS/1% agar noble (DIFCO) was applied with additional 5 ml overlays added on days 5 and 9. ONYX-330 and -340 were constructed in a similar fashion, using the plasmids pSN-p16NhePme and pSN-H-ras.N17NhePme, respectively, as described above (EcoRI cut and ligation) using 293 cells with a standard CaPO 4 transfection method. 47 Virus screening and propagation Individual plaques were propagated in 3.5-cm plates of A549 or 293 cells in DME/2% FBS. Cells and medium were collected, frozen and thawed three times and viral DNA was isolated from a 200 l aliquot using the QIAamp DNA blood kit (Qiagen). PCR primers specific for the transgene and for the E3 region were used to identify the appropriate virus which was then plaque purified, reconfirmed, and purified on a CsCl gradient. Final stock viruses were confirmed by PCR, sequencing, and Hirt analysis. 48 Enzymatic assay for CD activity Ten-cm plates of sub-confluent A549 cells were infected at an MOI (multiplicity of infection) of 10 in 2 ml of DME with 8 ml of DME/2% FBS added 1 p.i. At various times p.i., cells were rinsed with cold PBS, collected, flashfrozen in dry ice/ethanol and stored at −80°C. Cell pellets were resuspended in 200 l of assay buffer (100 mm Tris/HCl (pH 8.0) 1 mm EDTA, 1 mm ␤-mercaptoethanol) and lysed by three cycles of freeze/thaw. After clarification, soluble protein content was quantified (Bio-Rad protein assay; Bio-Rad, Hercules, CA, USA) and CD activity was assayed by thin layer chromatography 49 or quantified 50 as described.
Quantification of mTNF by ELISA
To measure levels of mTNF secreted into the culture medium of infected cells, the Cytoscreen mTNF kit (BioSource International, Camarillo, CA, USA. No. KMC3012) was used as described by the manufacturer. Four replicate plates per infection were used. Samples were obtained from the conditioned medium that had been incubated on the cells for 1 h and were diluted to ensure a value within the range of the standard curve. This was performed in duplicate and normalized for the number of cells.
Western blot analysis from wild-type and recombinant adenoviruses Subconfluent A549 or U2OS cells in 6-cm plates were infected at an MOI of 10 for 1 h in 1 ml of DME and then brought to 5 ml with DME/2% FBS. At various times p.i., cell monolayers were rinsed in PBS, collected, lysed in ELB buffer (50 mm Hepes, pH 7.4, 250 mm NaCl, 0.1% NP-40, 10 mm ␤-glycerophosphate, 1 mm NaF, 1 mm EDTA, 1 mm DTT) plus the protease inhibitor cocktail, Complete (Roche, Indianapolis, IN, USA), and frozen/thawed three times before being clarified by centrifugation. Twenty or 50 g of total protein (Bio-Rad protein assay; Bio-Rad, Hercules, CA, USA) was denatured in Laemmli buffer 51 at 95°C for 4 min, separated on a 4-20% SDS-PAGE Tris-glycine gradient gel (Novex, San Diego, CA, USA), and transferred to PVDF (Hybond-P, Amersham, Piscataway, NJ, USA; or Immobilon, Millipore, Bedford, MA, USA) membranes using a wet-transfer system (Bio-Rad).
A rabbit polyclonal antibody generated to CD following injection of a KLH-conjugated peptide corresponding to the C-terminal 15 amino acids of the E. coli CD (SynPep Corp, Dublin, CA, USA) was affinity-purified and used at a 1:50 000 dilution for Western blot analysis. Primary antibodies reacting against H-ras (mouse monoclonal F235; Santa Cruz (Santa Cruz, CA, USA) used at 0.1 mg/ml), p16 (rabbit polyclonal C-20; Santa Cruz used at 0.1 mg/ml), mTNF (goat polyclonal; R&D systems (Minneapolis, MN, USA) used at 0.1 g/ml), E3-gp19 K, 16 E3-ADP (Hawkins and Wold, unpublished data), E3-RID␤, 52 E3-14.7 K 53 (all E3 antibodies are rabbit polyclonals obtained from Dr WSM Wold, used at a 1:500 dilution), or against the Ad5 virion (American Qualex, Los Angeles, CA, USA; used at 1:1000) were incubated for 1-2 h in blocking solution TNT (50 mm Tris, pH 8.0, 150 mm NaCl, and 0.1% Tween-20) plus 5% non-fat dry milk. The membranes were incubated with secondary anti-mouse or anti-rabbit IgG antibodies conjugated to horseradish peroxidase (Amersham, used at 1:1000 dilution) for 1 h at 25°C and the signal was visualized using either the ECL or ECL plus system (Amersham).
